Idiopathic membranous nephropathy: Back to the future?

The Lancet

Volumn 381, Issue 9868, 2013, Pages 706-708

  Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BONE MARROW TOXICITY; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; NEPHROTIC SYNDROME; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; SIDE EFFECT; SKIN CANCER; TREATMENT DURATION;

EID: 84874414871     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62033-9     Document Type: Note

References (14)

1. Garattini S, Bertani T, Remuzzi G. Steroids and cytotoxic drugs in the treatment of membranous glomerulopathy. Nephron 1988; 50: 263-64.
2. Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis 2004; 44: 562-66.
3. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89.
4. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004; 44: 385-401.
5. Davison AM, Cameron JS, Kerr DN, Ogg CS, Wilkinson RW. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984; 22: 61-67.
6. Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8-13.
7. Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47: 1130-35.
8. Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; published online Jan 9. http://dx.doi.org/10.1016/S0140-6736(12)61566-9.
9. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-50.
10. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-904.
11. International Con ference on Harmonisation of Tech nical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1). June 10, 1996. http://www.ich.org/fileadmin/Public-Web-Site/ ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf (accessed Dec 18, 2012).
12. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 100-05.
13. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
14. Appel GB. Rituximab in membranous nephropathy: is it a first-line treatment? J Am Soc Nephrol 2012; 23: 1280-82.